OncoMatch/Clinical Trials/NCT05334693

Expanded Haploidentical Natural Killer Cells as Consolidation Strategy for Children/Young Adults With AML

Is NCT05334693 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Expanded haploidentical NK cells for acute myeloid leukemia.

Phase 1/2RecruitingBelarusian Research Center for Pediatric Oncology, Hematology and ImmunologyNCT05334693Data as of May 2026

Treatment: Expanded haploidentical NK cells — The purpose of this study is to estimate the efficacy of immunotherapy with ex vivo expanded haploidentical NK cells as consolidation therapy for children/young adults with intermediate risk AML.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Myeloid Leukemia

Lab requirements

Liver function

sgot or scpt <5x upper limit of normal for age

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify